Steven Shoelson

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Banking on ATM as a new target in metabolic syndrome
    Steven E Shoelson
    Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA
    Cell Metab 4:337-8. 2006
  2. ncbi Metabolic syndrome, insulin resistance, and roles of inflammation--mechanisms and therapeutic targets
    Giulio R Romeo
    Joslin Diabetes Center, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 32:1771-6. 2012
  3. ncbi Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance
    S E Shoelson
    Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02215, USA
    Int J Obes Relat Metab Disord 27:S49-52. 2003
  4. ncbi Inflammation and insulin resistance
    Steven E Shoelson
    Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Clin Invest 116:1793-801. 2006
  5. ncbi Obesity, inflammation, and insulin resistance
    Steven E Shoelson
    Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    Gastroenterology 132:2169-80. 2007
  6. ncbi Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters
    Markus Feuerer
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Joslin Diabetes Center, Boston, Massachusetts, USA
    Nat Med 15:930-9. 2009
  7. ncbi SH2 and PTB domain interactions in tyrosine kinase signal transduction
    S E Shoelson
    Department of Medicine, Harvard Medical School and Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA
    Curr Opin Chem Biol 1:227-34. 1997
  8. ncbi Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta
    M Yuan
    Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02215, USA
    Science 293:1673-7. 2001
  9. ncbi Crystal structure of the tyrosine phosphatase SHP-2
    P Hof
    Joslin Diabetes Center and the Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA
    Cell 92:441-50. 1998
  10. ncbi Evidence for a role for the phosphotyrosine-binding domain of Shc in interleukin 2 signaling
    K S Ravichandran
    Division of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 93:5275-80. 1996

Research Grants

  1. TOLL RECEPTOR ACTIVATION OF NF-kB IN INSULIN RESISTANCE AND T2DM
    Steven Shoelson; Fiscal Year: 2009
  2. Ser/Thr Phosphorylation in Insulin Resistance
    Steven Shoelson; Fiscal Year: 2007
  3. IKK MEDIATED INSULIN RESISTANCE AND IN VIVO REVERSAL
    Steven Shoelson; Fiscal Year: 2004
  4. TOLL RECEPTOR ACTIVATION OF NF-kB IN INSULIN RESISTANCE AND T2DM
    Steven Shoelson; Fiscal Year: 2007
  5. MEDIATORS AND MODIFIERS OF NF-kappaB IN INSULIN RESISTANCE
    Steven Shoelson; Fiscal Year: 2007
  6. TOLL RECEPTOR ACTIVATION OF NF-kB IN INSULIN RESISTANCE AND T2DM
    Steven E Shoelson; Fiscal Year: 2010
  7. EFFECTS OF IKKB and NFkB IN INSULIN RESISTANCE
    Steven Shoelson; Fiscal Year: 2009
  8. Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate
    Steven Shoelson; Fiscal Year: 2007
  9. Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate
    Steven Shoelson; Fiscal Year: 2007
  10. STRUCTURE OF IRS PROTEINS IN INSULIN RESISTANCE
    Steven Shoelson; Fiscal Year: 2002

Collaborators

  • Jongsoon Lee
  • Tony Pawson
  • Ali Nayer
  • Giulio R Romeo
  • Diane Mathis
  • Michael Karin
  • JEFFREY FLIER
  • Christopher Walsh
  • L C Cantley
  • Feng Liu
  • David Nolan
  • LAURIE GOODYEAR
  • Allison Goldfine
  • Gerald Shulman
  • David J Glass
  • Kitt Falk Petersen
  • Joel K Elmquist
  • Dongsheng Cai
  • Peter A Melendez
  • Eric D Werner
  • Markus Feuerer
  • Amy Fleischman
  • Watip Boonyasrisawat
  • Andisheh Abedini
  • Richard C Ho
  • Minsheng Yuan
  • Lone Hansen
  • Alessandro Doria
  • Kerilyn R Wick
  • S Dhe-Paganon
  • Ripudaman S Hundal
  • Claudia Menzaghi
  • M J Eck
  • M Yuan
  • J D Frantz
  • R T Nolte
  • Daniela Cipolletta
  • Laura Herrero
  • Afia Naaz
  • Christophe Benoist
  • Jamie Wong
  • Raquel Bernier
  • Simonetta Bacci
  • Michael T Johnstone
  • Vincenzo Trischitta
  • Yuan-yuan Zhang
  • Delphine Eberle
  • Ernest V Gervino
  • Yuan Yuan Zhang
  • P Hof
  • E A Ottinger
  • C Bjørbaek
  • William G Aschenbach
  • Jocelyn R Farmer
  • Michael F Hirshman
  • Daniel F Frantz
  • Z Songyang
  • Carol A Witczak
  • Yangfeng Li
  • Walter R Frontera
  • Per Olof Hasselgren
  • Byung Chul Oh
  • Byung-Chul Oh
  • Nicholas E Tawa
  • J Daniel Frantz
  • M L Lupher
  • Per-Olof Hasselgren
  • Hart G W Lidov
  • Paul Langlais
  • Sirano Dhe-Paganon
  • Lily Q Dong
  • Fresnida J Ramos
  • Pritpal S Randhawa
  • Xiaowei Ma
  • Nattachet Plengvidhya
  • Silvio Inzucchi
  • James H Warram
  • H Band
  • K S Ravichandran
  • Adam B Mayerson
  • N Konstantopoulos
  • L Hansen
  • Z W Li
  • T Fukazawa
  • S Pluskey
  • S Giorgetti-Peraldi
  • S C Harrison
  • V Igras
  • S W Fesik
  • J Schlessinger

Detail Information

Publications30

  1. ncbi Banking on ATM as a new target in metabolic syndrome
    Steven E Shoelson
    Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA
    Cell Metab 4:337-8. 2006
    ..These findings provide potential new insights into the pathogenesis and treatment of metabolic syndrome...
  2. ncbi Metabolic syndrome, insulin resistance, and roles of inflammation--mechanisms and therapeutic targets
    Giulio R Romeo
    Joslin Diabetes Center, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 32:1771-6. 2012
    ..In this context, ongoing clinical studies are testing the effects of targeting inflammation systemically on metabolic and cardiovascular outcomes...
  3. ncbi Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance
    S E Shoelson
    Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02215, USA
    Int J Obes Relat Metab Disord 27:S49-52. 2003
    ....
  4. ncbi Inflammation and insulin resistance
    Steven E Shoelson
    Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Clin Invest 116:1793-801. 2006
    ....
  5. ncbi Obesity, inflammation, and insulin resistance
    Steven E Shoelson
    Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    Gastroenterology 132:2169-80. 2007
    ..We review the rapidly expanding body of animal and clinical data that support potential roles for inflammation in the pathogenesis of insulin resistance and type 2 diabetes mellitus...
  6. ncbi Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters
    Markus Feuerer
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Joslin Diabetes Center, Boston, Massachusetts, USA
    Nat Med 15:930-9. 2009
    ..These observations suggest that harnessing the anti-inflammatory properties of T(reg) cells to inhibit elements of the metabolic syndrome may have therapeutic potential...
  7. ncbi SH2 and PTB domain interactions in tyrosine kinase signal transduction
    S E Shoelson
    Department of Medicine, Harvard Medical School and Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA
    Curr Opin Chem Biol 1:227-34. 1997
    ..Recent advances with small peptides and nonpeptide compounds suggest that this opportunity can be realized...
  8. ncbi Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta
    M Yuan
    Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 02215, USA
    Science 293:1673-7. 2001
    ..These findings implicate an inflammatory process in the pathogenesis of insulin resistance in obesity and type 2 diabetes mellitus and identify the IKKbeta pathway as a target for insulin sensitization...
  9. ncbi Crystal structure of the tyrosine phosphatase SHP-2
    P Hof
    Joslin Diabetes Center and the Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA
    Cell 92:441-50. 1998
    ..Recognition of bisphosphorylated ligands by the tandem SH2 domains is an integral element of this switch; the C-terminal SH2 domain contributes binding energy and specificity, but it does not have a direct role in activation...
  10. ncbi Evidence for a role for the phosphotyrosine-binding domain of Shc in interleukin 2 signaling
    K S Ravichandran
    Division of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 93:5275-80. 1996
    ..Taken together, our in vivo and in vitro observations suggest that the PTB domain of Shc interacts with Y338 of the IL-2R and provide evidence for a functional role for the Shc-PTB domain in IL-2 signaling...
  11. ncbi The Cbl phosphotyrosine-binding domain selects a D(N/D)XpY motif and binds to the Tyr292 negative regulatory phosphorylation site of ZAP-70
    M L Lupher
    Lymphocyte Biology Section, Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Biol Chem 272:33140-4. 1997
    ..These results identify a potential Cbl-PTB domain-dependent role for Cbl in the negative regulation of ZAP-70 and predict potential Cbl-PTB domain binding sites on other protein tyrosine kinases known to interact with Cbl...
  12. ncbi Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav
    Z Songyang
    Department of Cell Biology, Harvard Medical School, Boston, Massachusetts
    Mol Cell Biol 14:2777-85. 1994
    ..SHC is predicted to bind to a subgroup og these same motifs. A structural basis for the association of Csk with Src family members is also suggested from these studies...
  13. ncbi Crystal structure of the pleckstrin homology-phosphotyrosine binding (PH-PTB) targeting region of insulin receptor substrate 1
    S Dhe-Paganon
    Joslin Diabetes Center and the Department of Medicine, Harvard Medical School, Boston, MA 02215, USA
    Proc Natl Acad Sci U S A 96:8378-83. 1999
    ....
  14. ncbi Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes
    R T Nolte
    Howard Hughes Medical Institute and Laboratory of Molecular Medicine, Children s Hospital, Boston, Massachusetts 02115, USA
    Nat Struct Biol 3:364-74. 1996
    ..The structures suggest a mechanism for the biological specificity exhibited by PI 3-kinase in its interactions with phosphoprotein partners...
  15. ncbi Kinetics of p56lck and p60src Src homology 2 domain binding to tyrosine-phosphorylated peptides determined by a competition assay or surface plasmon resonance
    G Payne
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115
    Proc Natl Acad Sci U S A 90:4902-6. 1993
    ..Lowest affinity (80- to 300-fold lower) was observed with phosphopeptides corresponding to phosphorylated tyrosines of GTPase-activating protein, insulin receptor substrate 1, and SH2 domain-containing protein-tyrosine-phosphatase 1...
  16. ncbi Human GRB-IRbeta/GRB10. Splice variants of an insulin and growth factor receptor-binding protein with PH and SH2 domains
    J D Frantz
    Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Biol Chem 272:2659-67. 1997
    ..We conclude that hGrb-IRbeta/Grb10 is a widely expressed, PH and SH2 domain-containing, SH3 domain-binding protein that functions downstream from activated insulin and growth factor receptors...
  17. ncbi Identification of SOCS-3 as a potential mediator of central leptin resistance
    C Bjørbaek
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Mol Cell 1:619-25. 1998
    ..In conclusion, SOCS-3 is a leptin-inducible inhibitor of leptin signaling, and a potential mediator of leptin resistance in obesity...
  18. ncbi T cell activation-dependent association between the p85 subunit of the phosphatidylinositol 3-kinase and Grb2/phospholipase C-gamma 1-binding phosphotyrosyl protein pp36/38
    T Fukazawa
    Department of Rheumatology and Immunology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Biol Chem 270:20177-82. 1995
    ..These results strongly suggest the role of pp36/38 in recruiting PI-3-K to the cell membrane and further support the idea that pp36/38 is a multifunctional docking protein for SH2 domain-containing signaling proteins in T cells...
  19. ncbi Inflammation and obesity: STAMPing out insulin resistance?
    Andisheh Abedini
    Immunol Cell Biol 85:399-400. 2007
  20. ncbi IKKbeta/NF-kappaB activation causes severe muscle wasting in mice
    Dongsheng Cai
    Research Division, Joslin Diabetes Center, One Joslin Place, Boston, MA 02215, USA
    Cell 119:285-98. 2004
    ....
  21. ncbi Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB
    Dongsheng Cai
    Joslin Diabetes Center and Department of Medicine, Harvard Medical School, One Joslin Place, Boston, Massachusetts 02215, USA
    Nat Med 11:183-90. 2005
    ..These findings indicate that lipid accumulation in the liver leads to subacute hepatic 'inflammation' through NF-kappaB activation and downstream cytokine production. This causes insulin resistance both locally in liver and systemically...
  22. ncbi Salsalate improves glycemia and inflammatory parameters in obese young adults
    Amy Fleischman
    Harvard Medical School, Boston, Massachusetts, USA
    Diabetes Care 31:289-94. 2008
    ..The aim of the current study was to evaluate the efficacy of the anti-inflammatory drug salsalate to improve glycemia by reducing systemic inflammation in obese adults at risk for the development of type 2 diabetes...
  23. ncbi Point-counterpoint: Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis
    Steven E Shoelson
    J Appl Physiol 102:820; author reply 825. 2007
  24. ncbi Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes
    Watip Boonyasrisawat
    Section on Genetics and Epidemiology, Joslin Diabetes Center, One Joslin Place, Boston, MA 02215, USA
    Diabetes 56:499-505. 2007
    ..04 and 0.028, respectively). These findings point to variability in the A20/TNFAIP3 gene as a modulator of CAD risk in type 2 diabetes. This effect is mediated by allelic differences in A20 expression...
  25. ncbi Regulation of IkappaB kinase and NF-kappaB in contracting adult rat skeletal muscle
    Richard C Ho
    Research Division, Joslin Diabetes Center, 1 Joslin Pl, Boston, Massachusetts 02215, USA
    Am J Physiol Cell Physiol 289:C794-801. 2005
    ..In conclusion, acute submaximal exercise transiently stimulates NF-kappaB signaling in skeletal muscle. This activation is a local event because it can occur in the absence of exercise-derived systemic factors...
  26. ncbi Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302
    Eric D Werner
    Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Biol Chem 279:35298-305. 2004
    ....
  27. ncbi Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)-phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the association of IRS-1/IRS-2 with the insulin receptor
    Kerilyn R Wick
    Department of Pharmacology, The University of Texas Health Science Center, San Antonio 78229, USA
    J Biol Chem 278:8460-7. 2003
    ..We conclude that binding of hGrb10gamma to IR decreases signaling through the IRS/PI 3-kinase/AKT pathway by physically blocking IRS access to IR...
  28. ncbi Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes
    Ripudaman S Hundal
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06536-8012, USA
    J Clin Invest 109:1321-6. 2002
    ..In conclusion, these data support the hypothesis that IKKbeta represents a new target for treating type 2 diabetes mellitus...
  29. ncbi Genetic variability in insulin action inhibitor Ikkbeta (IKBKB) does not play a major role in the development of type 2 diabetes
    Claudia Menzaghi
    Research Division, Joslin Diabetes Center, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Clin Endocrinol Metab 87:1894-7. 2002
    ..We conclude that sequence differences in the IKBKB gene do not play a major role in either early-onset, autosomal dominant type 2 diabetes, or common forms with a later-onset...
  30. ncbi Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5
    Dongsheng Cai
    Joslin Diabetes Center and the Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Biol Chem 278:25323-30. 2003
    ..IRS6/DOK5 neither associates with these Src homology 2 domains nor activates MAPK. IRS5/DOK4 and IRS6/DOK5 represent two new signaling proteins with potential roles in insulin and IGF-1 action...

Research Grants49

  1. TOLL RECEPTOR ACTIVATION OF NF-kB IN INSULIN RESISTANCE AND T2DM
    Steven Shoelson; Fiscal Year: 2009
    ..abstract_text> ..
  2. Ser/Thr Phosphorylation in Insulin Resistance
    Steven Shoelson; Fiscal Year: 2007
    ..These studies should provide a growing framework for understanding major mechanisms of insulin resistance in obesity, T2D and the metabolic syndrome. ..
  3. IKK MEDIATED INSULIN RESISTANCE AND IN VIVO REVERSAL
    Steven Shoelson; Fiscal Year: 2004
    ..Finally, clinical studies are proposed to determine whether IKKb inhibition reverses insulin resistance in humans with impaired glucose tolerance. ..
  4. TOLL RECEPTOR ACTIVATION OF NF-kB IN INSULIN RESISTANCE AND T2DM
    Steven Shoelson; Fiscal Year: 2007
    ..The findings will improve our understanding of the role of subacute 'inflammation' in insulin resistance, T2D and the metabolic syndrome, and may identify new and more selective targets for therapeutic intervention. ..
  5. MEDIATORS AND MODIFIERS OF NF-kappaB IN INSULIN RESISTANCE
    Steven Shoelson; Fiscal Year: 2007
    ..The findings will improve our understanding of the role of subacute 'inflammation' in insulin resistance, T2D and the metabolic syndrome, and may identify new and more selective targets for therapeutic intervention. ..
  6. TOLL RECEPTOR ACTIVATION OF NF-kB IN INSULIN RESISTANCE AND T2DM
    Steven E Shoelson; Fiscal Year: 2010
    ..abstract_text> ..
  7. EFFECTS OF IKKB and NFkB IN INSULIN RESISTANCE
    Steven Shoelson; Fiscal Year: 2009
    ..abstract_text> ..
  8. Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate
    Steven Shoelson; Fiscal Year: 2007
    ..abstract_text> ..
  9. Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate
    Steven Shoelson; Fiscal Year: 2007
    ....
  10. STRUCTURE OF IRS PROTEINS IN INSULIN RESISTANCE
    Steven Shoelson; Fiscal Year: 2002
    ....
  11. RECEPTOR/SUBSTRATE COMPLEXES IN TRANSMEMBRANE SIGNALING
    Steven Shoelson; Fiscal Year: 1999
    ..Since related or identical mechanisms likely occur in additional receptor signaling pathways, proposed studies should also interest those working in many areas of oncology, endocrinology and immunology. ..
  12. MAPPING THE INSULIN-RECEPTOR INTERFACE
    Steven Shoelson; Fiscal Year: 1993
    ....